Commentary: Malignant Glaucoma - Have we finally found an answer?

Selective allodepletion: have we finally found the holy grail?

Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment option for patients with hematologic malignancies and nonmalignant disorders of hematopoiesis. Outcomes of allogeneic HSCT have improved steadily over the decades [1]. However, significant challenges remain. One of these challenges is the so-called Holy Grail of stem cell transplantation immunology: to...

Editorial comment: Adenosine in heart transplants: have we finally found the good indication?

Statins: have we found the Holy Grail?

In coronary artery disease, cardiovascular risk factors are the main targets for primary and secondary prevention. Statins prevent cardiovascular events in patients at risk. However, despite the proven efficacy and safety of statins, relevant side effects exist and should be considered when treating patients.

PFO and cryptogenic stroke: Do we finally have closure?

In up to 40 percent of patients with acute ischemic stroke, the etiology remains uncertain [1]. The association of a PFO with stroke in a young woman with cerebral arterial embolism was first described in 1877 [2]. Lechat et al. later described the high prevalence of PFO in adults younger than 55 years of age when no identifiable cause of stroke could be identified [3]. They suggested that para...

Sleeve gastrectomy: have we finally found the holy grail of bariatric surgery? A review of the literature.

OBJECTIVE Laparoscopic sleeve gastrectomy has become one of the most commonly performed bariatric operations. It is essentially a restrictive bariatric operation; however, a series of hormonal changes occurring postoperatively contribute to decreased appetite and reduced food intake. PATIENTS AND METHODS This is a literature review of recent articles published on Pubmed, Medline and Google Sc...